Nasdaq Biotech Profile (AVCO) Surges Early, Could Be Building Significant Support At Key Levels

AVCO is off to a hot start this morning. Nasdaq Biotech Profile (AVCO) Surges Early, Could Be Building Significant Support At Key Levels January 31st Dear Reader, AVCO is off to a hot start this morning. Sprinting out of the opening bell, AVCO is currently trending green and could be picking up steam. Hitting an early high of $.84, AVCO is now trading above [several lines of potential support.]( Those lines include its: - 5-Day Simple Moving Average (SMA) - 20-Day SMA - 5-Day Exponential Moving Average (EMA) - 13-Day EMA If potential support starts building stronger and stronger at those levels, it could provide a starting block for this Nasdaq profile to continue on a vertical move near term. Could we see AVCO return to previous highs? [With a float]( in the neighborhood of 33Mn shares, it could happen quickly due to potential volatility. Take a moment and read my initial report below. Then get AVCO front and center this morning. ----- Cancer. What an ugly disease. At this point, we all have known at least a few people who have been directly impacted by cancer. Good news is, there are companies out there aiming to battle cancer into submission. Cellular immunotherapy is an innovative treatment approach that harnesses the body’s own immune system to fight cancer. [The global cellular immunotherapy market]( is expected to grow from $2.74Bn in 2020 to $3.59Bn in 2021. The market is expected to reach $6.73Bn in 2025. One company I've been keeping track of is appearing to be making major headway in cellular immunotherapy along with several other interesting health related therapies/treatments. And due to several potential catalysts, it could be on the verge of doing something special. So for Monday, January 31st, there is only one Nasdaq biotech idea to have on your radar: *Avalon GloboCare Corp. (AVCO)* Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. And right now, the company has several potential catalysts that could spark a near term vertical chart move. They include: #1. - End Of Year Business Update, Focus On 2022 #2. - Chairman Provides De-bt Con-version #3. - Company Advances AI-Enhanced Protein Design Tech #4. - Filing US & International Patent Application For Breakthrough Tech So let's break those down quickly... #1. AVCO Potential Catalyst - End Of Year Business Update, Focus On 2022 Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update. [...] [Read the full article here.]( ----- #2. AVCO Potential Catalyst - Chairman Provides Debt Conversion Avalon GloboCare’s Chairman Converts Debt into Common St-ock at 45% Premium to Market FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0Mn of debt owed to him under the Line of Credit into 2.4 million shares of the Company’s common st-ock at $1.25 per share. The conversion price represents a 45% premium to yesterday’s closing price. [...] [Read the full article here.]( ----- #3. AVCO Potential Catalyst - Company Advances AI-Enhanced Protein Design Tech Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development FREEHOLD, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced further advancement of the Company’s sponsored research and licensing agreement with the Massachusetts Institute of Technology (MIT). Avalon and MIT have combined their artificial intelligence (AI)-enhanced protein design “QTY Code” technology with Google’s AlphaFold2, a DeepMind AI program developed to predict 3-dimensional (3D) protein structures of previously difficult to work with dr-ug targets. This new system is designed to accelerate and advance Avalon’s capabilities in developing novel targets for immuno-oncology and cellular medicine. [...] “This new study with our collaborator, Dr. Shuguang Zhang from MIT, has validated the innovative application of the QTY code technology to transform important cellular therapy targets that have been previously difficult to work with in the laboratory,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This new approach is advancing our capabilities in designing novel immuno-oncology and cellular medicine therapies and we are excited to continue to work with Dr. Zhang to advance these dr-ug development technologies,” added Dr. Jin. [...] [Read the full article here.]( ----- #4. AVCO Potential Catalyst - Filing US & International Patent Application For Breakthrough Tech Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Dr-ug Delivery and Cellular Immunotherapy FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), [...], today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next generation drug delivery and cellular immunotherapy [...]. [...] “We are very excited to announce this novel SLET platform, which we believe will help accelerate the development of our mRNA-based Flash-CAR™ program. The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy. In addition, we see a number of other therapeutic and diagnostic applications for this broad and potentially transformative technology platform. Moreover, we believe these latest patent filings will provide us robust international IP protection for this technology and its many potential applications,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. [Read the full article now.]( ----- AVCO Recap - 4 Potential Driver Indicators For This Nasdaq Biotech Idea #1. - End Of Year Business Update, Focus On 2022 #2. - Chairman Provides De-bt Con-version #3. - Company Advances AI-Enhanced Protein Design Tech #4. - Filing US & International Patent Application For Breakthrough Tech ----- Coverage is officially initiated on AVCO. When you have time later, do this: Get AVCO on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). I am not a lic-ensed fina-ncial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between FierceInvestor (FI) and SWN Media LLC, FI was hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. We were paid five thousand USD via ACH. We own zero shares of (AVCO). An owner of SWN Media LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (AVCO). Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net